Email Updates

You are here

AVAC in the News

  • On July 16, 2012, the Food and Drug Administration (FDA) approved Truvada for pre-exposure prophylaxis—better known as PrEP—to prevent HIV acquisition. But although uptake has improved over the past decade, PrEP still isn’t reaching everyone at risk for HIV.

    July 16, 2022
    POZ Magazine
  • On July 16, 2012, the Food and Drug Administration (FDA) approved Truvada for pre-exposure prophylaxis—better known as PrEP—to prevent HIV acquisition. But although uptake has improved over the past decade, PrEP still isn’t reaching everyone at risk for HIV. Truvada (TDF/FTC) contains two drugs, tenofovir disoproxil fumarate and emtricitabine, that are widely used for HIV treatment.

    July 16, 2022
    POZ Magazine
  • HIV care has come a long way in the more than 40 years since the Centers for Disease Control and Prevention published the first report of AIDS in June 1981. The combined efforts of researchers, clinicians, public health officials, activists and people living with HIV have led to amazing advances in prevention and treatment. And despite many setbacks, cure research is also making progress.

    June 27, 2022
    POZ Magazine
  • Melb Simiyu, an HIV prevention officer at a support organization for sex workers here, says most of her clients have asked when a drug called CAB-LA will become available. Approved by the US Food and Drug Administration (FDA) in December 2021, the HIV prevention drug could drastically reduce infections among marginalized groups like the one she works with.

    June 24, 2022
    Science
  • Melb Simiyu, an HIV prevention officer at a support organization for sex workers here, says most of her clients have asked when a drug called CAB-LA will become available. Approved by the U.S. Food and Drug Administration (FDA) in December 2021, the HIV prevention drug could drastically reduce infections among marginalized groups like the one she works with. But even though a trial in Uganda and six other sub-Saharan African countries provided data key for FDA’s approval, Africa, still the part of the world hardest hit by HIV, may face a long wait to get the drug at an affordable price.

    June 21, 2022
    Science
  • Wednesday, May 18, is HIV Vaccine Awareness Day (HVAD) 2022. It’s an exciting time for vaccine research, marked by the speed with which COVID-19 vaccines were developed. At the same time, the seemingly fast advances in the field led many to wonder, Where is the vaccine to protect against HIV? HVAD offers a chance to explore these topics and to thank the researchers, advocates and volunteers involved in HIV vaccine development.

    May 18, 2022
    POZ
  • For over 2 years, the world has been riveted by progress and pitfalls of the COVID-19 pandemic and subsequent vaccine development and rollout. However, alongside scientific milestones of COVID-19 vaccines, there have been significant results from HIV vaccine and antibody-mediated prevention trials. These include the first proof of concept of HIV prevention from passive antibodies and recent insights on the possibility of germline targeting and the mRNA platform towards an effective HIV vaccine.

    May 17, 2022
    JIAS
  • At a 2016 workshop in Chennai to understand people’s hope for a human immunodeficiency virus (HIV) vaccine, a participant said such a vaccine may make society more “morally corrupt”. He believed that a preventive vaccine may encourage more people to engage in unsafe sex with multiple partners. The respondent had HIV and had experienced stigma and discrimination.

    May 16, 2022
    Nature
  • The US Senate has confirmed Dr. John Nkengasong as the US global AIDS coordinator, which will include leadership of the US President's Emergency Plan for AIDS Relief — the US global HIV initiative. The Cameroonian virologist is the first person born on the African continent to take on the role. He currently serves as the director of the Africa Centres for Disease Control and Prevention.

    May 6, 2022
    General
    Devex
  • With almost half the world fully vaccinated against the pandemic, we can look at the glass as either half full or half empty — it depends on where you are and who you are. The lowest vaccination rates can be found in low-income or low-middle income countries, and among the most marginalized populations within nearly every country. So while COVID-19 vaccine development is a great example of scientific progress, its delivery reflects tragic inequity.

    April 5, 2022
    General
    The Hill

Pages